Please see the article here for a Q+A interview with Dunad CEO Pearl Huang in Nature Reviews Drug Discovery.
NT-0796 successfully completes Phase 1 study, demonstrating blood-brain barrier penetration and reduced inflammatory biomarkers supporting advancement in neuroinflammatory and peripheral inflammatory diseases Second clinical candidate
Edinburgh and Cambridge, UK, 12 September 2022 – Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, is pleased to announce that Dr
Pegcetacoplan treatment effect accelerated between months 18-24, demonstrating a robust reduction of GA lesion growth compared to sham (all p-values are nominal) DERBY: 36% monthly,
Dr. Huang brings more than 30 years of biopharma experience, most recently as Chief Executive Officer and President of Flagship Pioneering start-up Cygnal Therapeutics Dunad
Andy Billinton PhD appointed as Chief Scientific Officer Expansion into larger facilities at the Babraham Research Campus Cambridge, 23rd June 2022: Transine Therapeutics today announced
Dr Alison Strutt joins Kynos senior management team as CFO Brings extensive strategic, transactional, and operational experience in biotech and large pharma to the Kynos
WALTHAM, Mass., June 01, 2022 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the
Company adds £4.6m additional seed funding Strengthens investor syndicate with Epidarex joining as a new investor Enhances ability to leverage unique SINEUP® platform and rapidly
Spin-out from the University of Edinburgh commercialising a decade of drug discovery research on kynurenine 3-monooxygenase (KMO), a pivotal enzyme in the kynurenine pathway of